Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)

9/28/23 4:32:06 PM ET

$RETA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RETA alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Desai Antal Rohit

(Last)

(First)

(Middle)

4215 WEST LOVERS LN., STE 100

(Street)

DALLAS

75209

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
REATA PHARMACEUTICALS INC [ RETA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock	09/26/2023		D		31,467	D	⁽⁴⁾	0	I⁽¹⁾⁽³⁾	By The 2:22 DNA Trust⁽¹⁾⁽³⁾
Class A common stock	09/26/2023		D		113	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By CPMG, Inc.⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		116,512	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Nighthawk Partners, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		282,246	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Willet Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		137,962	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Killdeer Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		5,464	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Elepaio Partners, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		44,200	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Barred Owl Partners, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		34,897	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Managed Account for Trustees of the University of Pennsylvania⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		442,560	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Gallopavo, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		748,253	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Roadrunner Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		431,155	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Yellow Warbler, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		109,415	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Mallard Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		37,909	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Crested Crane, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		334,740	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Sandpiper Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		160,265	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Kestrel Fund, LP(⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		11,076	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By CD Fund, LP⁽²⁾⁽³⁾
Class A common stock	09/26/2023		D		134	D	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Redbird Life Sciences Partners, LP⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B common stock	⁽⁵⁾	09/26/2023		D			1,251	⁽⁵⁾	⁽⁵⁾	Class A common stock	1,251	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By CPMG, Inc.⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			150,186	⁽⁵⁾	⁽⁵⁾	Class A common stock	150,186	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Mallard Fund, LP⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			307,776	⁽⁵⁾	⁽⁵⁾	Class A common stock	307,776	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Kestrel Fund, LP⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			123,279	⁽⁵⁾	⁽⁵⁾	Class A common stock	123,279	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By CD Fund, LP⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			1,490	⁽⁵⁾	⁽⁵⁾	Class A common stock	1,490	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Redbird Life Sciences Partners, LP⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			114,946	⁽⁵⁾	⁽⁵⁾	Class A common stock	114,946	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Willet Fund, LP⁽²⁾⁽³⁾
Class B common stock	⁽⁵⁾	09/26/2023		D			993,929	⁽⁵⁾	⁽⁵⁾	Class A common stock	993,929	⁽⁴⁾	0	I⁽²⁾⁽³⁾	By Yellow Warbler, LP⁽²⁾⁽³⁾

1. Name and Address of Reporting Person^*

Desai Antal Rohit

(Last)

(First)

(Middle)

4215 WEST LOVERS LN., STE 100

(Street)

DALLAS

75209

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

CPMG Inc

(Last)

(First)

(Middle)

4215 WEST LOVERS LN., STE 100

(Street)

DALLAS

75209

(City)

(State)

(Zip)

Explanation of Responses:

1. Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust.

2. CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4.

3. Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

4. Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes.

5. The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date.

Remarks:

Mr. McGaughy, Jr. serves on the Issuer's Board of Directors (the "Board") as a representative of CPMG, Inc. By virtue of his representation on the Board, for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors of the Issuer by deputization of Mr. McGaughy, Jr.

	/s/ Antal Rohit Desai	09/28/2023
	/s/ John Bateman, Chief Operating Officer of CPMG, Inc.	09/28/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $RETA alert in real time by email

Date	Price Target	Rating	Analyst
7/6/2023	$140.00	Outperform	TD Cowen
6/12/2023	$80.00 → $115.00	Market Perform → Outperform	SVB Securities
10/19/2022	$75.00	Buy	Guggenheim
3/24/2022	$91.00	Buy	Goldman
3/1/2022	$39.00 → $34.00	Neutral	Goldman Sachs
12/9/2021	$39.00	Buy → Neutral	Goldman Sachs
12/9/2021	$110.00 → $37.00	Outperform → Neutral	Robert W. Baird
12/9/2021	$112.00 → $68.00	Overweight	Cantor Fitzgerald

Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)

Chat with this insight

Recent Analyst Ratings for $RETA

$RETA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

$RETA Leadership Updates

Live Leadership Updates

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

$RETA SEC Filings

SEC Form 15-12G filed by Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

SEC Form POSASR filed by Reata Pharmaceuticals Inc.

$RETA Press Releases

Fastest customizable press release news feed in the world

$RETA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$RETA Financials

Live finance-specific insights

$RETA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$RETA Market Insights

Live Market Insights

$RETA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Biogen Completes Acquisition of Reata Pharmaceuticals

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA